What is Gilead's exposure from GSK's patent lawsuit against Biktarvy®, Gilead's new integrase inhibitor HIV therapy?

Gilead’s new HIV drug, Biktarvy®, has received FDA approval. Almost immediately, Gilead was hit with a patent-infringement lawsuit by ViiV Healthcare, which is owned by GSK, along with Pfizer and Shionogi. What is Gilead’s exposure?

Markman AdvisorsFebruary 8, 2018Gilead, GlaxoKlineSmith, Pfizer, Biktarvy, HIV therapy, Shionogi, ViiV Healthcare, patent, Descovy, Triumeq, Juluca, bictegravir, tivicay Comments

Blog